Bictegravir, emtricitabine, and tenofovir alafenamide (Oral)
Medically reviewed by Drugs.com. Last updated on Mar 13, 2022.
Warning: Post treatment acute exacerbation of hepatitis BSevere acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and hepatitis B virus (HBV) and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of bictegravir/emtricitabine/tenofovir alafenamide.Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue bictegravir/emtricitabine/tenofovir alafenamide. If appropriate, anti-hepatitis B therapy may be warranted .
Commonly used brand name(s)
In the U.S.
- Biktarvy
Available Dosage Forms:
- Tablet
Therapeutic Class: Antiviral
Pharmacologic Class: Integrase Inhibitor
Uses for bictegravir, emtricitabine, and tenofovir alafenamide
Bictegravir, emtricitabine, and tenofovir alafenamide combination is used alone to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). Bictegravir, emtricitabine, and tenofovir alafenamide is usually given to patients who have yet to receive any medicine for their HIV infection or to patients to replace their current medicine provided that they meet certain requirements.
Bictegravir, emtricitabine, and tenofovir alafenamide combination will not cure or prevent HIV infection or AIDS. It works by lowering the amount of HIV in the blood and will also help your immune system. This may help delay problems that are usually related to AIDS or HIV disease from occurring. Bictegravir, emtricitabine, and tenofovir alafenamide will not keep you from spreading HIV to other people. People who receive bictegravir, emtricitabine, and tenofovir alafenamide may continue to have other problems usually related to AIDS or HIV disease.
Bictegravir, emtricitabine, and tenofovir alafenamide is available only with your doctor's prescription.
Before using bictegravir, emtricitabine, and tenofovir alafenamide
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For bictegravir, emtricitabine, and tenofovir alafenamide, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to bictegravir, emtricitabine, and tenofovir alafenamide or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of bictegravir, emtricitabine, and tenofovir alafenamide combination in children weighing less than 14 kilograms (kg). Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of bictegravir, emtricitabine, and tenofovir alafenamide combination in..
